Will Investors Profit from Geron's Road to Recovery?

The Food and Drug Administration recently lifted a partial hold on Geron's (NASDAQ: GERN  ) imetelstat for a trial in myelofibrosis. The drug has shown great efficacy data so far, sending myelofibrosis patients into complete remission -- something Incyte's (NASDAQ: INCY  ) Jakafi, the only approved drug for myelofibrosis, can't do.

But the trial that was reinstated was just an investigator-sponsored trial. To release the clinical hold on company-run trials in essential thrombocythemia, polycythemia vera, and multiple myeloma, Geron has to present more preclinical data and analyze the clinical data to convince the FDA that imetelstat isn't causing permanent liver damage.

Watch the video below for more thoughts from senior biotech specialist Brian Orelli and health-care analyst David Williamson on Geron's prospects and whether Incyte has anything to worry about.

Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.


Read/Post Comments (0) | Recommend This Article (4)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 3004511, ~/Articles/ArticleHandler.aspx, 10/31/2014 3:57:42 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement